{"title":"VCL::ROS1：新一代测序检测到的新型 ROS1 致癌融合体。","authors":"Anurag Mehta, Himanshi Diwan, Shrinidhi Nathany, Ullas Batra, Manoj Gupta, Manoj Kumar Panigrahi, Dushyant Kumar, Sakshi Mattoo, Aayushi Singh","doi":"10.1177/2632010X241269373","DOIUrl":null,"url":null,"abstract":"<p><p>Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with <i>ROS1</i> gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners documented in the existing literature. Our report highlights a novel fusion partner of <i>ROS1</i> that has demonstrated a conclusive response to the current standard of treatment.</p>","PeriodicalId":53204,"journal":{"name":"Clinical Pathology","volume":"17 ","pages":"2632010X241269373"},"PeriodicalIF":1.9000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11320388/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>VCL::ROS1</i>: A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing.\",\"authors\":\"Anurag Mehta, Himanshi Diwan, Shrinidhi Nathany, Ullas Batra, Manoj Gupta, Manoj Kumar Panigrahi, Dushyant Kumar, Sakshi Mattoo, Aayushi Singh\",\"doi\":\"10.1177/2632010X241269373\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with <i>ROS1</i> gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners documented in the existing literature. Our report highlights a novel fusion partner of <i>ROS1</i> that has demonstrated a conclusive response to the current standard of treatment.</p>\",\"PeriodicalId\":53204,\"journal\":{\"name\":\"Clinical Pathology\",\"volume\":\"17 \",\"pages\":\"2632010X241269373\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11320388/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/2632010X241269373\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2632010X241269373","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}
VCL::ROS1: A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing.
Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with ROS1 gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners documented in the existing literature. Our report highlights a novel fusion partner of ROS1 that has demonstrated a conclusive response to the current standard of treatment.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
